InterAx Biotech AG
Novel safe and efficacious drugs with AI and cell biology.
InterAx developed a drug discovery and optimisation technology platform to go beyond target identification and ligand discovery. It is connecting AI and cell signalling to design drugs triggering a precisely defined cell pathway modulation. This unique combination enables to identify and optimise safer and more efficacious drug candidates rather than just generating them faster and cheaper, thus significantly de-risk their development process.
InterAx focuses on the design of drugs targeting G-Protein-Coupled Receptors, the largest class of human cellular receptors and targets of 40% of all marketed.
InterAx offers biopharma partners in need to gain in-depth insight for the design of high-quality drug candidates access to its technology platform.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
14.02.2024
InterAx Biotech's AI platform unlocks new drug designs for diabetes, obesity, and cancer (venturelab.swiss)
27.11.2023
European grants fuel the development of new solutions (startupticker.ch)
24.10.2023
Startups appoint industry mavens to their board of directors (startupticker.ch)
21.07.2022
Ten Biotech startups brace for Boston (startupticker.ch)
17.06.2022
Plug and play Basel welcomes its first cohort (startupticker.ch)
Last Tweets
14.04.2020
No Jobs
No videos and documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders China
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
InterAx Biotech AG
Novel safe and efficacious drugs with AI and cell biology.
Website:
www.interaxbiotech.com
Headquarter:
Villigen
Foundation Date:
April 2016
Technology:
- Biotech
Sectors:
- Bioinformatics
- Biotech
- Cancer
- Drug discovery
- Inflammation
- Neurology
- Protein drugs
- Screening
- Small molecule drugs
Support received
